

Louise Emmett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4739301/publications.pdf>

Version: 2024-02-01

95
papers

5,791
citations

109321

35
h-index

76900

74
g-index

97
all docs

97
docs citations

97
times ranked

4999
citing authors

#	ARTICLE	IF	CITATIONS
1	¹⁷⁷ Lu-PSMA-617 and Idronexil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. Journal of Nuclear Medicine, 2022, 63, 560-566.	5.0	22
2	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clinical and Translational Radiation Oncology, 2022, 32, 41-47.	1.7	7
3	Side effects of therapy with radiolabelled prostate specific membrane antigen (PSMA). , 2022, , .		0
4	Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.	6.4	18
5	High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU International, 2022, 130, 5-7.	2.5	10
6	All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others. European Urology Oncology, 2022, 5, 283-284.	5.4	2
7	Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups. BJU International, 2022, 130, 32-39.	2.5	11
8	Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 1015-1024.	0.8	18
9	18F-PSMA-11 as an Attractive 68Ga-PSMA-11 Alternative for Prostate Cancer Imaging. European Urology, 2022, , .	1.9	0
10	Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronexil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). European Urology Oncology, 2021, 4, 963-970.	5.4	27
11	68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 477-482.	6.4	54
12	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	1.2	7
13	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	6.4	188
14	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.	13.7	552
15	UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU International, 2021, 128, 331-342.	2.5	33
16	Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology, 2021, 299, 248-260.	7.3	38
17	Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncology, 2021, 17, 2225-2241.	2.4	14
18	ENZA-1 trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 2021, 128, 642-651.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. <i>Advances in Urology</i> , 2021, 2021, 1-9.	1.3	13
20	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. <i>European Urology</i> , 2021, 80, 234-242.	1.9	35
21	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021, 80, 682-689.	1.9	181
22	Qualitative study of nuclear medicine physicians' perceptions of positron emission tomography/computed tomography in pregnant patients with cancer. <i>Internal Medicine Journal</i> , 2021, 51, 1722-1726.	0.8	3
23	Editorial Comment. <i>Journal of Urology</i> , 2021, , 101097JU000000000000225401.	0.4	0
24	3-Year Freedom from Progression After ⁶⁸ Ga-PSMA PET/CTâ€“Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 866-872.	5.0	86
25	Use of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. <i>BJU International</i> , 2020, 125, 206-214.	2.5	80
26	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 546-555.	0.8	42
27	Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151052.	1.5	3
28	Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. <i>Melanoma Research</i> , 2020, 30, 358-363.	1.2	14
29	Clinical impact of PET imaging in prostate cancer management. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 649-653.	1.8	1
30	Prospective evaluation of the impact of human papilloma virus status and small node size on the diagnostic accuracy of 18F â€fluorodeoxyglucose positron emission tomography/computed tomography for primary head and neck squamous cell carcinoma. <i>ANZ Journal of Surgery</i> , 2020, 90, 1396-1401.	0.7	2
31	Distribution of prostate cancer recurrences on galliumâ€68 prostateâ€specific membrane antigen (⁶⁸ Gaâ€PSMA) positronâ€emission/computed tomography after radical prostatectomy with pathological nodeâ€positive extended lymph node dissection. <i>BJU International</i> , 2020, 125, 876-883.	2.5	10
32	Protocol for the PRIMARY clinical trial, a prospective, multicentre, crossâ€sectional study of the additive diagnostic value of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. <i>BJU International</i> , 2020, 125, 515-524.	2.5	51
33	TheraP: A randomised phase II trial of ¹⁷⁷ Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5500-5500.	1.6	58
34	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 99-99.	0.4	0
35	Galliumâ€68â€prostateâ€specific membrane antigen (⁶⁸ Ga^{â€PSMA}) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediateâ€and highâ€risk prostate cancer. <i>BJU International</i> , 2019, 124, 62-68.	2.5	53
36	Diagnostic accuracy of ⁶⁸ Gaâ€prostateâ€specific membrane antigen (^{PSMA}) positronâ€emission tomography (^{PET}) and multiparametric (mp)^{MRI} to detect intermediateâ€grade intraâ€prostatic prostate cancer using wholeâ€mount pathology: impact of the addition of ⁶⁸ Gaâ€^{PSMA PET} to mp^{MRI}. <i>BJU International</i> , 2019, 124, 42-49.	2.5	80

#	ARTICLE	IF	CITATIONS
37	Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?. <i>European Urology</i> , 2019, 76, 479-481.	1.9	7
38	TheraP: a randomized phase 2 trial of ¹⁷⁷ Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol) https://doi.org/10.1186/s12916-019-1501-0	15.0	10
39	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2019, 140, 68-75.	0.6	20
40	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 961-971.	10.7	126
41	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸ F-Fluoromethylcholine or ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1253-1258.	5.0	24
42	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	7.1	493
43	Asymptomatic Prostate Cancer Brain Metastases on ⁶⁸ Ga-PSMA PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e382-e384.	1.3	14
44	Exceptional Response to ¹⁷⁷ Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	3.0	10
45	⁶⁸ Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. <i>British Journal of Radiology</i> , 2019, 92, 20180667.	2.2	16
46	Prospective, Multisite, International Comparison of ¹⁸ F-Fluoromethylcholine PET/CT, Multiparametric MRI, and ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 794-800.	5.0	61
47	Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial ⁶⁸ Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. <i>Journal of Nuclear Medicine</i> , 2019, 60, 950-954.	5.0	133
48	Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 15-22.	1.9	131
49	⁶⁸ Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 343-346.	1.1	30
50	Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2018, 38, 159-162.	3.8	3
51	The Impact of ⁶⁸ Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 82-88.	5.0	281
52	Delineating sites of failure following post-prostatectomy radiation treatment using ⁶⁸ Ga-PSMA-PET. <i>Radiotherapy and Oncology</i> , 2018, 126, 244-248.	0.6	27
53	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.	2.2	25
54	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2018, 129, 377-386.	0.6	39

#	ARTICLE	IF	CITATIONS
55	Prospective evaluation of ⁶⁸ Gallium prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. <i>BJU International</i> , 2017, 119, 209-215.	2.5	263
56	⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	5.0	111
57	Frusemide aids diagnostic interpretation of ⁶⁸ Ga-PSMA positron emission tomography/CT in men with prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 739-744.	1.8	23
58	Development of standardized image interpretation for ⁶⁸ Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	6.4	91
59	Futility of imaging to stage melanoma patients with a positive sentinel lymph node. <i>Melanoma Research</i> , 2017, 27, 457-462.	1.2	15
60	Initial multicentre experience of ⁶⁸ Ga-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. <i>BJU International</i> , 2017, 120, 673-681.	2.5	67
61	Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. <i>Journal of Medical Radiation Sciences</i> , 2017, 64, 52-60.	1.5	222
62	Delineating biochemical failure with ⁶⁸ Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 99-102.	0.6	38
63	Treatment Outcomes from ⁶⁸ Ga-PSMA PET/CT "Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1972-1976.	5.0	149
64	Impact of Patient Preparation on the Diagnostic Performance of ¹⁸ F-FDG PET in Cardiac Sarcoidosis. <i>Clinical Nuclear Medicine</i> , 2016, 41, e327-e339.	1.3	72
65	SPECT-CT versus VQ versus CTPA for diagnosing pulmonary embolus and other lung pathology: Pre-existing lung disease should not be a contraindication. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 492-497.	1.8	21
66	⁶⁸ Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. <i>BJU International</i> , 2016, 117, 732-739.	2.5	239
67	Schwannoma Showing Avid Uptake on ⁶⁸ Ga-PSMA-HBED-CC PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 703-704.	1.3	30
68	Brown Adipose Tissue Exhibits a Glucose-Responsive Thermogenic Biorhythm in Humans. <i>Cell Metabolism</i> , 2016, 23, 602-609.	16.2	149
69	Prognostic and Diagnostic Implications of Nonperfusion Data on SPECT Myocardial Perfusion Imaging. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.6	0
70	Prospective Comparison of ¹⁸ F-Fluoromethylcholine Versus ⁶⁸ Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1185-1190.	5.0	516
71	Granulomatous sarcoid aortitis: a serious complication of a well-known multisystem disease. <i>Lancet</i> , The, 2015, 385, 2014.	13.7	7
72	Sentinel lymph node mapping for defining site and extent of elective radiotherapy management of regional nodes in Merkel cell carcinoma: A pilot case series. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 353-359.	1.8	7

#	ARTICLE	IF	CITATIONS
73	Comparative assessment of rest and post-stress left ventricular volumes and left ventricular ejection fraction on gated myocardial perfusion imaging (MPI) and echocardiography in patients with transient ischaemic dilation on adenosine MPI: Myocardial stunning or subendocardial hypoperfusion?. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 735-742.	2.1	30
74	Hypophosphataemic Osteomalacia in Patients on Adefovir Dipivoxil. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 468-473.	2.2	41
75	Progressive Visual Loss Due to Obstruction of an Optic Nerve Sheath Fenestration Demonstrated on SPECT/CT Radionuclide Cisternography. <i>Clinical Nuclear Medicine</i> , 2010, 35, 208-210.	1.3	2
76	Severe Ischaemia on SPECT Myocardial Perfusion Imaging Secondary to Microvascular Dysfunction and Apical Hypertrophic Cardiomyopathy. <i>Clinical Nuclear Medicine</i> , 2010, 35, 937-940.	1.3	2
77	Effect of unilateral endobronchial valve insertion on pulmonary ventilation and perfusion: A pilot study. <i>Respirology</i> , 2010, 15, 1079-1083.	2.3	23
78	Hypophosphatemic Osteomalacia after Low-Dose Adefovir Dipivoxil Therapy for Hepatitis B. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 479-480.	3.6	37
79	Increased In-111 Octreotide Uptake due to Paget Disease and a Low Midline Pelvic Kidney. <i>Clinical Nuclear Medicine</i> , 2009, 34, 84-86.	1.3	2
80	Hypertrophic Pulmonary Osteoarthropathy Demonstrated on SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 628-631.	1.3	13
81	Prospective evaluation of the impact of diabetes and left ventricular hypertrophy on the relationship between ischemia and transient ischemic dilation of the left ventricle on single-day adenosine Tc-99m myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2008, 15, 638-643.	2.1	18
82	SPECT/CT of Femoroacetabular Impingement. <i>Clinical Nuclear Medicine</i> , 2008, 33, 757-762.	1.3	26
83	Natural History of Right Ventricular Dysfunction After Acute Pulmonary Embolism. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 885-894.	2.8	37
84	Atrial and Ventricular Echocardiographic Correlates of the Extent of Pulmonary Embolism in the Elderly. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 347-353.	2.8	25
85	Electrocardiographic prediction of the severity of posterior wall perfusion defects on rest technetium-99m Sestamibi myocardial perfusion imaging. <i>Journal of Electrocardiology</i> , 2005, 38, 195-203.	0.9	1
86	The role of left ventricular hypertrophy and diabetes in the presence of transient ischemic dilation of the left ventricle on myocardial perfusion SPECT images. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1596-601.	5.0	34
87	Rhabdomyolysis Resulting From Interaction of Simvastatin and Clarithromycin Demonstrated by Tc-99m MDP Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2004, 29, 803-804.	1.3	24
88	A Critical Appraisal of Pinhole Scintigraphy of the Ankle and Foot. <i>Clinical Nuclear Medicine</i> , 2002, 27, 707-710.	1.3	4
89	Reversible regional wall motion abnormalities on exercise technetium-99m gated cardiac single photon emission computed tomography predict high-grade angiographic stenoses. <i>Journal of the American College of Cardiology</i> , 2002, 39, 991-998.	2.8	112
90	SPET of a computerised model of diffuse lung disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 150-154.	2.1	4

#	ARTICLE	IF	CITATIONS
91	Paraspinal Abscess Complicating Facet Joint Injection. <i>Clinical Nuclear Medicine</i> , 2000, 25, 71.	1.3	46
92	Sequestered Collection in Association With Infected Arthroplasty. <i>Clinical Nuclear Medicine</i> , 2000, 25, 288-289.	1.3	1
93	Sunburst Periosteal Reaction in a Bony Metastasis. <i>Clinical Nuclear Medicine</i> , 2000, 25, 392-393.	1.3	2
94	<i>Eikenella Corrodens</i> Vertebral Osteomyelitis. <i>Clinical Nuclear Medicine</i> , 2000, 25, 1059-1060.	1.3	11
95	Pain in the Anterior Pelvis and Postoperative Prostatectomy Findings. <i>Clinical Nuclear Medicine</i> , 1999, 24, 523-524.	1.3	0